Stockreport

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience, Inc.  (SKYE) 
PDF Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts;Received writt [Read more]